Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Baseline information - Cognitively Unimpaired (CU)

From: Association of modifiable risk factors with progression to dementia in relation to amyloid and tau pathology

Amyloid

n

All (n = 434)

Amyloid positive (n = 152)

Amyloid negative (n = 282)

statistics

Age: mean (SD) years

434

73.3 ( 6.2)

74.7 ( 5.9)

72.5 ( 6.2)

t = -4.3,df = 346.0,p = < .0001 *

Baseline MMSE

434

29.1 ( 1.2)

29.0 ( 1.1)

29.1 ( 1.2)

t = 0.1, df = 363.2, p = 0.9501

ApoE4 carrier status

434

124 ( 28.6%)

70 ( 46.1%)

54 ( 19.1%)

ChiSq = 35.0,df = 1.0,p = < .0001 *

Baseline Hippocampus Volume (mm3)

434

7483 ( 864)

7336 ( 860)

7562 ( 857)

t = 2.6, df = 307.7, p = 0.0089

Female gender: n (%)

434

240 ( 55.3%)

94 ( 61.8%)

146 ( 51.8%)

ChiSq = 4.1, df = 1.0, p = 0.0441

Higher CAIDE score: n (%)

428

131 ( 30.6%)

48 ( 31.8%)

83 ( 30.0%)

ChiSq = 0.2, df = 1.0, p = 0.6956

CAIDE Total Score

428

5.8 ( 1.5)

5.8 ( 1.5)

5.8 ( 1.4)

t = -0.3, df = 318.7, p = 0.7691

Depression as risk: n (%)

434

74 ( 17.1%)

28 ( 18.4%)

46 ( 16.3%)

ChiSq = 0.3, df = 1.0, p = 0.5773

Smokers: n (%)

356

40 ( 11.2%)

17 ( 13.6%)

23 ( 10.0%)

ChiSq = 1.1, df = 1.0, p = 0.2988

Follow-up time: median(IQR)

434

48 ( 24- 96)

48 ( 24- 90)

60 ( 24- 96)

ChiSq = 3.2, df = 1.0, p = 0.0724

Progression to MCI or dementia: n (%)

434

83 ( 19.1%)

38 ( 25.0%)

45 ( 16.0%)

ChiSq = 5.2, df = 1.0, p = 0.0223

p-tau181

n

All (n = 331)

p-tau181 positive (n = 114)

p-tau181 negative (n = 217)

statistics

Age: mean (SD) years

331

74.0 ( 5.8)

75.7 ( 6.1)

73.1 ( 5.4)

t = -3.9,df = 220.4,p = 0.0001 *

Baseline MMSE

331

29.0 ( 1.2)

29.0 ( 1.2)

29.0 ( 1.1)

t = 0.1, df = 227.2, p = 0.8962

ApoE4 carrier status

331

88 ( 26.6%)

39 ( 34.2%)

49 ( 22.6%)

ChiSq = 5.2, df = 1.0, p = 0.0229

Baseline Hippocampus Volume (mm3)

331

7452 ( 856)

7313 ( 881)

7525 ( 836)

t = 2.1, df = 219.4, p = 0.0354

Female gender: n (%)

331

171 ( 51.7%)

59 ( 51.8%)

112 ( 51.6%)

ChiSq = 0.0, df = 1.0, p = 0.9805

Higher CAIDE score: n (%)

327

105 ( 32.1%)

41 ( 36.6%)

64 ( 29.8%)

ChiSq = 1.6, df = 1.0, p = 0.2087

CAIDE Total Score

327

5.8 ( 1.5)

5.9 ( 1.5)

5.8 ( 1.5)

t = -0.7, df = 241.3, p = 0.5003

Depression as risk: n (%)

331

68 ( 20.5%)

23 ( 20.2%)

45 ( 20.7%)

ChiSq = 0.0, df = 1.0, p = 0.9043

Smokers: n (%)

331

37 ( 11.2%)

10 ( 8.8%)

27 ( 12.4%)

ChiSq = 1.0, df = 1.0, p = 0.3139

Follow-up time: median(IQR)

331

72 ( 36–102)

66 ( 36- 96)

72 ( 36–102)

ChiSq = 0.1, df = 1.0, p = 0.7322

Progression to MCI or dementia: n (%)

331

72 ( 21.8%)

39 ( 34.2%)

33 ( 15.2%)

ChiSq = 15.9,df = 1.0, p = < .0001 *

Amyloid and p-tau181

n

All (n = 219)

Amyloid and p-tau181 positive (n = 60)

Amyloid and p-tau181 negative (n = 159)

statistics

Age: mean (SD) years

219

73.7 ( 5.6)

76.4 ( 5.2)

72.6 ( 5.5)

t = -5.1,df = 119.5,p = < .0001 *

Baseline MMSE

219

29.1 ( 1.2)

29.1 ( 1.1)

29.1 ( 1.2)

t = -0.4, df = 122.3, p = 0.6813

ApoE4 carrier status

219

56 ( 25.6%)

28 ( 46.7%)

28 ( 17.6%)

ChiSq = 19.3,df = 1.0,p = < .0001 *

Baseline Hippocampus Volume (mm3)

219

7492 ( 800)

7245 ( 817)

7585 ( 776)

t = 2.8, df = 101.7, p = 0.0064

Female gender: n (%)

219

109 ( 49.8%)

33 ( 55.0%)

76 ( 47.8%)

ChiSq = 0.9, df = 1.0, p = 0.3418

Higher CAIDE score: n (%)

216

70 ( 32.4%)

23 ( 39.0%)

47 ( 29.9%)

ChiSq = 1.6, df = 1.0, p = 0.2056

CAIDE Total Score

216

5.8 ( 1.5)

5.9 ( 1.5)

5.8 ( 1.5)

t = -0.7, df = 108.2, p = 0.5080

Depression as risk: n (%)

219

42 ( 19.2%)

12 ( 20.0%)

30 ( 18.9%)

ChiSq = 0.0, df = 1.0, p = 0.8495

Smokers: n (%)

219

22 ( 10.0%)

6 ( 10.0%)

16 ( 10.1%)

ChiSq = 0.0, df = 1.0, p = 0.9890

Follow-up time: median(IQR)

219

72 ( 36- 96)

54 ( 36- 90)

72 ( 36–102)

ChiSq = 4.7, df = 1.0, p = 0.0305

Progression to MCI or dementia: n(%)

219

46 ( 21.0%)

23 ( 38.3%)

23 ( 14.5%)

ChiSq = 15.0,df = 1.0,p = 0.0001 *

  1. CU Cognitively Unimpaired, MCI Mild Cognitive Impairment, MMSE Mini-Mental State Examination, ApoE4 Apolipoprotein E epsilon 4 carriers, CAIDE Cardiovascular Risk Factors, Aging, and Dementia, p-tau181 Phosphorylated tau 181, CSF Cerebrospinal Fluid, n Number of participants, SD Standard Deviation, IQR Interquartile Range, ChiSq Chi-Square Test, df Degrees of Freedom, p p-value
  2. *p-values indicate significant differences between biomarker positives and negatives (after correction for multiple comparisons p < 0.05/11, where 11 is the number of parameters compared), and are based on T-tests or Wilcoxon tests (follow-up time) in case of continuous variables and Chi-Square tests in case of categorical variables
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193